Parliamentary Search

Written question asked by Baroness Masham of Ilton (Crossbench) on Tuesday, 18 May 2021, in the House of Lords. It was due for an answer on Wednesday, 2 June 2021. It was answered by Lord Bethell (Conservative) on Friday, 28 May 2021 on behalf of the Department of Health and Social Care.

Asthma: Dupilumab

Question

To ask Her Majesty's Government what assessment they have made of the decision by the National Institute for Health and Clinical Excellence not to recommend dupilumab for the treatment of severe asthma with Type 2 inflammation in their appraisal constitution document; and what assessment they have made of its recent approval by the Scottish Medicines Consortium for use in Scotland.

Answer

The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for assessing new medicines and treatments in accordance with its existing methods and processes. NICE’s draft guidance on dupilumab for consultation of 7 May 2021 states that it is not recommended for the treatment of severe asthma. NICE has not yet published its final recommendations on dupilumab and the draft guidance is now open for consultation until 28 May 2021. There will be a further meeting of NICE’s independent appraisal committee in September to consider all comments received during the consultation.

The Government has not made any assessment of the decision of the Scottish Medicines Consortium on dupilumab, as this is a devolved matter.

Secondary information

Type
Written question
Reference
HL366
Session
2021-22
Subjects
Scotland Asthma Dupilumab
Link
View this Written question on www.parliament.uk